Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity

Abstract

Background In recent studies, microRNAs (mi-RNAs) have been shown to play an important role in psoriasis pathogenesis. However, studies evaluating mi-RNAs in the blood of psoriasis patients including a large number of mi-RNA panels are scarce. Objective The authors aimed to assess mi-RNA expressions in blood samples of psoriasis patients, as well as to evaluate the association between mi-RNA expression and psoriasis severity. Methods This was a case-control study on 52 patients with psoriasis vulgaris and 54 controls. Patients’ medical history, psoriasis area and severity index (PASI) scores, and dermatology life quality index (DLQI) scores were recorded. The 42 disease-related mi-RNA primers were assessed by real-time PCR. Results In the patient group, 13.4% presented nail involvement and 8.2% had psoriatic arthritis. The mean PASI and DLQI scores were 7.90 ± 8.83 and 8.13 ± 5.50, respectively. Among 42 mi-RNA primers; hsa-miR-155-5p, hsa-miR-369-3p, hsa-miR-193b-3p, hsa-miR-498, hsa-miR-1266-5p, hsa-let-7d-5p, hsa-miR-205-5p, hsa-let-7c-5p, hsa-miR-30b-3p, and hsa-miR-515-3p expressions were significantly up-regulated, whereas hsa-miR-21-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-223-3p, hsa-miR-26a-5p, hsa-miR-106b-5p, hsa-miR-126-5p, hsa-miR-181a-5p, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-24-3p, hsa-miR-17-3p, hsa-miR-30b-5p, hsa-miR-130a-3p, hsa-miR-30e-5p, and hsa-miR-16-5p were significantly down-regulated in psoriasis patients when compared with the control group ( p < 0.05). Study limitations As the study included patients with mild to moderate psoriasis who mostly only received topical treatments, changes in miRNA before and after systemic treatments were not assessed. Conclusion The detection of 24 mi-RNA expressions up- or down-regulated in psoriasis patients, even in those with milder disease, further supports the role of mi-RNAs in the psoriasis pathogenesis. Future studies should clarify whether mi-RNAs can be used as a marker for psoriasis prognosis or as a therapeutic agent in the treatment of psoriasis.

MicroRNA-17-3p is upregulated in psoriasis and regulates keratinocyte hyperproliferation and pro-inflammatory cytokine secretion by targeting <em>CTR9</em>

“…Consistently, in our research, we detected increased miR-173p expression in the psoriasis skin lesions. In contrast to the present study, miR-17-3p expression levels were downregulated in blood samples of psoriasis patients, 23 this contradictory result may be due to the fact that the majority of patients with psoriasis included in the study by Atalas et al presented milder disease, while the patients had severe diseases in our study, or due to the fact that blood mainly includes immune cells, while epidermis mainly contains keratinocytes, implying that miR-17-3p may have different expression patterns in the two types of cells.…”

Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases

“…Alatas et al discovered that expressions of miR-155-5p along with other miRNAs significantly increased in patients diagnosed with psoriasis compared with the control group. However, disease severity was not correlated with miRNAs (167).…”

microRNAs involved in psoriasis and cardiovascular diseases

“…miR-369 expression levels were found increased in serum samples and skin tissues deriving from psoriatic patients compared to healthy subjects and a positive correlation exists between skin miR-369 levels and PASI (64,75). miR-369 has emerged as a key regulator of inflammatory response in dendritic cells, since it decreases LPS-induced NO production, by targeting directly iNOS expression, and simultaneously inhibiting nuclear translocation of NF-kB (76).…”

“…miR-369 expression levels were found to be increased in serum samples and skin tissues deriving from psoriatic patients compared to healthy subjects, and a positive correlation existed between skin miR-369 levels and PASI ( 64 , 75 ).…”

“…miR-22 circulating expression levels were significantly downregulated in the blood of patients affected by psoriasis vulgaris compared to healthy subjects ( 64 ). In addition, plasma levels of miR-22 were evaluated in PsA and ankylosing spondylitis, two chronic inflammatory rheumatic disorders.…”